A new systemic nutrition-inflammation index predicted perioperative non-small cell lung cancer outcomes better than current ...

The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...

Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

A multivariate analysis confirmed the independent prognostic significance of both landmark and longitudinal MRD.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

TEPMETKO is a kinase inhibitor prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) carrying MET exon 14 skipping alterations. The active component is Tepotinib (as ...

Non-small cell lung cancer (NSCLC) is the most common type ... market is expected to grow with advances in biomarker-driven therapy, further refining patient selection. TEPMETKO's success will ...